44 results on '"Lip, G."'
Search Results
2. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: comment
3. Stroke in atrial fibrillation and improving the identification of ‘high-risk’ patients: the crossroads of immunity and thrombosis
4. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2)
5. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study
6. Retinal vein and artery occlusions: a risk factor for stroke in atrial fibrillation
7. Psychological influence of the media on patients commencing oral anticoagulation in atrial fibrillation; a qualitative analysis: PB 3.48–6
8. Predictive value of the HAS-BLED score in patients with atrial fibrillation and chronic kidney disease using vitamin K-antagonists: PB 3.40–4
9. Predictive value of the HAS-BLED score for major bleeding in patients with venous thromboembolism during anticoagulant treatment: PA 3.20–1
10. Fibrin monomers improves CHA2DS2-VASc risk prediction in chronically anticoagulated atrial fibrillation patients: PA 1.11–6
11. Stopping oral anticoagulation and the risk of thrombotic events and mortality in patients with atrial fibrillation: OC 79.5
12. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review
13. Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta-analysis of risk-modifying drugs
14. Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary
15. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation: a reply to a rebuttal
16. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study
17. Monocyte-derived and CD34+/KDR+ endothelial progenitor cells in heart failure
18. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction
19. Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation
20. Atrial fibrillation and upper limb thromboembolectomy: a national cohort study
21. Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort
22. Safety and tolerability of the oral factor Xa inhibitor, YM150 vs. warfarin in 1297 patients with nonvalvular atrial fibrillation: a dose confirmation study (OPAL-2): O-TH-083
23. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis
24. Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study
25. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology
26. Hemostatic cardiovascular risk factors, common carotid–intima medial thickness and peripheral arterial disease in South Asians and African Caribbeans: a substudy to the Ethnic-Echocardiographic Heart of England Screening (E-ECHOES) Study
27. A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice
28. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis
29. Omega-3 polyunsaturated acids and cardiovascular disease: notable ethnic differences or unfulfilled promise?
30. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis
31. Initiation and persistence of warfarin or aspirin as thromboprophylaxis in chronic atrial fibrillation in general practice
32. Circulating endothelial cells in health and disease: how do we best quantify them?
33. Circulating endothelial cells: from bench to clinical practice
34. Standardization of circulating endothelial cell enumeration by the use of human umbilical vein endothelial cells
35. Circulating endothelial cells and von Willebrand factor as indices of endothelial damage/dysfunction in coronary artery disease: a comparison of central vs. peripheral levels and effects of coronary angioplasty
36. Platelet activation and cardiovascular outcomes in acute coronary syndromes
37. Endotoxemia enhances circulating endothelial cells in humans
38. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990–1999
39. Angiogenin: a review of the pathophysiology and potential clinical applications
40. The prothrombotic risk of diabetes mellitus in atrial fibrillation and heart failure
41. Plasma von Willebrand factor levels and surrogates of atherosclerosis
42. RAISED CIRCULATING ENDOTHELIAL CELLS IN RHEUMATOID AND EARLY ARTHRITIS
43. Which is the ideal plasma marker of endothelial damage/dysfunction in atrial fibrillation? A comparison of von Willebrand factor, E-selectin and soluble thrombomodulin
44. Increased platelet adhesion in metastatic cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.